Join your peers and colleagues in San Francisco to gain insight and perspective on why molecular liquid biopsies have the potential to become a fulcrum in the future of precision medicine.
Circulating Tumor DNA Detection from Heparinized Plasma Samples by Droplet Di...Kate Barlow
Nasrin Sarafan-Vasseur, Liquid Biopsy Scientific Leader, Research Team on Oncology (IRON), INSERM and University of Rouen, France
Heparin is often used as plasma anticoagulant for tumor marker analysis but corresponds also to an inhibitory of PCR not enabling circulating tumor DNA (ctDNA) detection, which has been highlighted as a potential “liquid biopsy”. We evaluated the impact of heparinase addition on heparinized plasma samples to allow ctDNA analysis. Circulating ESR1 and KRAS mutations were quantified by digital PCR, in plasma collected in heparinized tubes (n=194) from hormone receptor-positive metastatic breast cancer (HR+MBC) and pancreatic adenocarcinoma (PA) patients. We improved significantly PCR efficiency in 91/144 HR+MBC and 26/50 PA plasma samples, enabling ctDNA detection in 22/91 and 13/26 patients. This new processing did not alter quantitatively and qualitatively ctDNA detection and could make the samples from heparinized blood-derived collections suitable for ctDNA analysis.
Importance of circulating tumour cells in patients with non-metastatic breast...Senology.org
The study found that the presence of circulating tumor cells (CTCs) in patients with early-stage breast cancer carried a higher risk of cancer recurrence or death. Patients with one or more CTCs had a four times greater risk, and those with three or more CTCs faced an 11.5 times higher risk of death from breast cancer. CTC levels did not correlate with lymph node status or primary tumor characteristics, suggesting CTC measurement provides additional prognostic information beyond standard analysis. However, larger studies are still needed to determine how best to use CTC information in clinical decision-making.
This document discusses early cancer detection technologies and methods. It begins with a debate on the pros and cons of early detection screening, then discusses the history of cervical cancer screening and its success. It also covers the high costs of cancer care. The bulk of the document focuses on liquid biopsy technologies for detecting cancer DNA in blood and their potential for early detection and monitoring. Specific technologies like Grail and Cologuard stool DNA testing are discussed. Challenges to adoption like guidelines, costs, regulation and education are also covered.
Overall, testing cfDNA has four distinct advantages over conventional biopsies, being:
Cost-effective approach;
Simplified sample collection procedures;
Reduced impact to the patient and;
Easily analyzed.
Liquid Biopsy Overview, Challenges and New Solutions: Liquid Biopsy Series Pa...QIAGEN
A liquid biopsy is often described as a sensitive and specific blood test to detect circulating tumor cells (CTCs). CTCs, shed by both the primary and metastasized tumors, carry specific information about their origins and markers that will enable us to discover new diagnosis, prognosis and therapeutic targets. This slidedeck gives an overview of the recent progress in exploring the predictive potential of circulating biomarkers, including circulating tumor cells, circulating tumor DNA, microRNAs, long non-coding RNAs (lncRNAs) and exosomes. Addressing both biological and technical aspects, we detail the isolation and characterization of circulating biomarkers. Challenges and solutions are also featured.
This document discusses liquid biopsy, a non-invasive technique to detect tumor biomarkers shed into body fluids like blood. It can identify circulating tumor cells, circulating tumor DNA, exosomes, and newly, tumor educated platelets. Liquid biopsy offers advantages over tissue biopsy like being less invasive, allowing repeated sampling over time. While sensitivity remains a limitation, liquid biopsy shows promise for early cancer detection, monitoring treatment response and tumor evolution, and assessing tumor heterogeneity. The document reviews technologies to analyze various biomarkers and potential clinical applications of liquid biopsy.
Circulating Tumor DNA Detection from Heparinized Plasma Samples by Droplet Di...Kate Barlow
Nasrin Sarafan-Vasseur, Liquid Biopsy Scientific Leader, Research Team on Oncology (IRON), INSERM and University of Rouen, France
Heparin is often used as plasma anticoagulant for tumor marker analysis but corresponds also to an inhibitory of PCR not enabling circulating tumor DNA (ctDNA) detection, which has been highlighted as a potential “liquid biopsy”. We evaluated the impact of heparinase addition on heparinized plasma samples to allow ctDNA analysis. Circulating ESR1 and KRAS mutations were quantified by digital PCR, in plasma collected in heparinized tubes (n=194) from hormone receptor-positive metastatic breast cancer (HR+MBC) and pancreatic adenocarcinoma (PA) patients. We improved significantly PCR efficiency in 91/144 HR+MBC and 26/50 PA plasma samples, enabling ctDNA detection in 22/91 and 13/26 patients. This new processing did not alter quantitatively and qualitatively ctDNA detection and could make the samples from heparinized blood-derived collections suitable for ctDNA analysis.
Importance of circulating tumour cells in patients with non-metastatic breast...Senology.org
The study found that the presence of circulating tumor cells (CTCs) in patients with early-stage breast cancer carried a higher risk of cancer recurrence or death. Patients with one or more CTCs had a four times greater risk, and those with three or more CTCs faced an 11.5 times higher risk of death from breast cancer. CTC levels did not correlate with lymph node status or primary tumor characteristics, suggesting CTC measurement provides additional prognostic information beyond standard analysis. However, larger studies are still needed to determine how best to use CTC information in clinical decision-making.
This document discusses early cancer detection technologies and methods. It begins with a debate on the pros and cons of early detection screening, then discusses the history of cervical cancer screening and its success. It also covers the high costs of cancer care. The bulk of the document focuses on liquid biopsy technologies for detecting cancer DNA in blood and their potential for early detection and monitoring. Specific technologies like Grail and Cologuard stool DNA testing are discussed. Challenges to adoption like guidelines, costs, regulation and education are also covered.
Overall, testing cfDNA has four distinct advantages over conventional biopsies, being:
Cost-effective approach;
Simplified sample collection procedures;
Reduced impact to the patient and;
Easily analyzed.
Liquid Biopsy Overview, Challenges and New Solutions: Liquid Biopsy Series Pa...QIAGEN
A liquid biopsy is often described as a sensitive and specific blood test to detect circulating tumor cells (CTCs). CTCs, shed by both the primary and metastasized tumors, carry specific information about their origins and markers that will enable us to discover new diagnosis, prognosis and therapeutic targets. This slidedeck gives an overview of the recent progress in exploring the predictive potential of circulating biomarkers, including circulating tumor cells, circulating tumor DNA, microRNAs, long non-coding RNAs (lncRNAs) and exosomes. Addressing both biological and technical aspects, we detail the isolation and characterization of circulating biomarkers. Challenges and solutions are also featured.
This document discusses liquid biopsy, a non-invasive technique to detect tumor biomarkers shed into body fluids like blood. It can identify circulating tumor cells, circulating tumor DNA, exosomes, and newly, tumor educated platelets. Liquid biopsy offers advantages over tissue biopsy like being less invasive, allowing repeated sampling over time. While sensitivity remains a limitation, liquid biopsy shows promise for early cancer detection, monitoring treatment response and tumor evolution, and assessing tumor heterogeneity. The document reviews technologies to analyze various biomarkers and potential clinical applications of liquid biopsy.
Using liquid biopsies to study cancer dynamics and drug resistanceSpeck&Tech
Liquid biopsies, which analyze cell-free DNA in blood, can be used to study cancer evolution and drug resistance over time. By tracking genetic mutations in plasma samples taken at different time points, researchers can create a temporal map of how a tumor changes with and without treatment. This approach has identified biomarkers of drug resistance and shown that tumors with higher levels of circulating tumor DNA have worse outcomes and are less responsive to some therapies. While liquid biopsies hold promise for early cancer detection and precision medicine, more large clinical studies are still needed to validate their clinical utility.
`Liquid biopsy' using blood test is latest weapon against cancerOther Mother
Researchers are testing a new "liquid biopsy" using blood tests that can detect tiny fragments of cancer DNA shed by tumors into the bloodstream. This less invasive method shows promise in determining if treatments are working and could be used to continuously monitor patients. Early results found the liquid biopsy predicted cancer recurrences over 3 months before CT scans in some cases. Oncologists hope this method may allow more personalized and effective cancer monitoring and treatment in the future.
Liquid biopsy quality control – the importance of plasma quality, sample prep...Thermo Fisher Scientific
Liquid biopsy is emerging as a non-invasive companion to traditional solid tumor biopsies. As next generation sequencing (NGS) of circulating cell-free nucleic acids (cfNA = cfDNA and cfRNA) becomes common, it’s important to understand the impact of sample preparation on quality, specificity, and sensitivity of liquid biopsy tests. Plasma samples are often limited, and may have undesirable characteristics such as lipemia or hemolysis that contribute unwanted genomic DNA (gDNA) to the sample. Low cfDNA concentration can also limit the amount available for NGS library prep. In this study, we explore the effects of suboptimal plasma and low library input on liquid biopsy NGS, and discuss various techniques for in-process quality control of cfNA samples isolated from plasma
Newer diagnostic tools in oncology such as liquid biopsies provide non-invasive approaches to diagnosing and monitoring cancer. Liquid biopsies analyze biomarkers found in bodily fluids and can detect circulating tumor cells, circulating tumor DNA, RNA, and exosomes shed by tumors into the bloodstream. These liquid biomarkers offer advantages over traditional tissue biopsies by being less invasive, able to capture the heterogeneity of tumors, and allow for real-time monitoring of treatment response and disease progression. Emerging technologies now allow liquid biopsies to provide genomic information that can help classify and treat cancers based on their molecular profiles rather than the organ or tissue of origin.
An overview of circulating cell-free DNA (cfDNA) as liquid biopsy biomarkers and the role of circulating tumour DNA (ctDNA) in advancing cancer research and diagnosis through non-invasive tumour mutation profiling
The Molecular Analysis on Circulating Tumor Cells to Determine Prognostic and...QIAGEN
Circulating tumor cells (CTCs) is an emerging source used molecular cancer diagnostics. Through expression profiling of CTCs, it allows a deeper understanding about which metabolic pathways enable tumor cells to survive in the circulation, how they become resistant to a drug regimen, how they transform and adapt and, finally, which cellular markers should targeted for future therapies.
This webinar will introduce the AdnaTest CTC detection platform which has been proven in several clinical trials to provide prognostic and predictive information in breast, ovarian and prostate cancer. The platform by itself is still open for research and allows access to any potential target of interest. Join us to learn more about this novel platform, its technology and applications in liquid biopsy.
This study aimed to develop an unbiased RNA profiling approach for the early detection of colorectal cancer (CRC) and advanced adenomas (AA) using blood samples. The researchers combined a literature review with microarray analysis of circulating RNA purified from plasma to identify RNA biomarker panels. They tested the panels on two cohorts, detecting CRC with 75% sensitivity and 93% specificity using an 8-gene panel, and detecting AA with 60% sensitivity and 87% specificity using a 2-gene panel. The study demonstrates the feasibility of unbiased molecular diagnosis of CRC and AA from blood and introduces circulating RNA profiling as a potential non-invasive screening approach.
This document discusses various minimally invasive interventions for liver tumors. It describes procedures such as transarterial chemoembolization (TACE), radiofrequency ablation (RFA), microwave ablation, cryoablation, ethanol ablation, and drug-eluting bead chemoembolization. For each procedure, it covers the mechanism of action, patient selection criteria, technical details, imaging guidance and follow up. It emphasizes that these minimally invasive therapies can be used to treat primary and secondary liver malignancies when surgery is not possible or as an adjunct to other treatments, with the aim of improving patient prognosis.
This document discusses tumor markers and their use in monitoring tumor response to therapy. It provides information on different types of tumor markers including proteins, enzymes, hormones, genetic markers and circulating tumor cells. Ideal tumor markers are highly sensitive and specific, correlate with tumor stage and prognosis, and can be used for screening, diagnosis, prognosis, monitoring treatment and detecting recurrence. Examples discussed include CEA, AFP, PSA, CA125 and circulating tumor cells. The Oncotype DX 21-gene recurrence score test and tissue polypeptide specific antigen are also summarized.
Surgery plays an important role in treating metastatic colorectal cancer. The document discusses:
1) The liver is the most common site of metastasis and surgical resection of isolated liver metastases can provide a 5-year survival rate of 45-60%, compared to just 6-9 months with no treatment.
2) Other potentially resectable isolated metastases, such as those in the lungs or peritoneum, may also be treated with surgery, providing 5-year survival rates around 20-40%.
3) Neoadjuvant chemotherapy can downsize initially unresectable liver metastases to make them resectable and improve long-term outcomes compared to surgery alone.
A tumor marker is a substance present in or produced by a tumor or by the tumor’s host in response to the tumor’s presence that can be used to differentiate a tumor from normal tissue or to determine the presence of a tumor based on measurement in the blood or secretions.
Maintrac liquid biopsy allows quantitative detection of circulating tumor cells without fixation, isolation, or enrichment. It uses fluorochrome-labeled antibody targeting EpCAM antigen on circulating tumor cells. In contrast, Cellsearch uses fixation and enrichment procedures that lead to loss of cells and antigenicity, resulting in dead cells. Comparison of the two methods using the same blood sample from a patient showed Maintrac detected more total events and circulating tumor cells than Cellsearch. Other CTC detection technologies have limitations such as relying too heavily on EpCAM expression or assuming CTCs are larger than blood cells. Cell-free tumor DNA analysis has problems like representing destroyed cells and additional mutations from DNA degradation.
Chapter 2.3 tumor biomarkers and vascular accessNilesh Kucha
This document discusses various tumor biomarkers, including what they are, their clinical uses, and specifics about common biomarkers like AFP, CA125, CA19-9, CA15-3, CEA, hCG, and PSA. It provides details on what types of cancers and conditions can cause elevations, reference ranges, half-lives, and how they are used for screening, diagnosis, prognosis, prediction, and monitoring of cancers. Ideal biomarkers are defined as highly specific and sensitive, correlating with tumor viability, reproducible, cheap, and detectable in occult disease.
The document discusses circulating tumor cells (CTCs) and their clinical applications. It summarizes the work of Brian Kirby's research group, which works at the interface of microfluidics, microtechnology, and cellular analysis. The group has developed a technique called GEDI (Geometrically Enhanced Differential Immunocapture) to isolate CTCs from blood samples. GEDI leverages fluid mechanical design and size-dependent interactions to maximize capture of rare CTCs while eliminating leukocytes. The group has used captured CTCs from castrate-resistant prostate cancer patients to functionally evaluate drug responses by examining markers like tubulin bundling and nuclear accumulation of the androgen receptor. They are currently conducting the
management of metastatic colorectal cancer Sujay Susikar
1) Metastatic colorectal cancer presents significant challenges, as around 40% of patients initially present with metastatic disease and 50% of those initially diagnosed without metastases will eventually develop them.
2) Management depends on whether metastases are synchronous or metachronous. For potentially resectable metastases, surgical resection offers the best chance of cure, with 5-year survival rates of 24-58% after resection of liver metastases.
3) For unresectable metastases, options include ablation techniques like radiofrequency ablation or cryotherapy, regional therapies like chemoembolization, systemic chemotherapy, and targeted agents. The goal is conversion to resectability with chemotherapy when possible.
Pancreatic cancer has a high mortality rate because it is often diagnosed late after metastasizing. Early detection is difficult because symptoms usually do not appear until it has spread. This paper aims to integrate multi-omic data like genomics, proteomics, and imaging into a predictive model to better classify pancreatic cancer patients. The goal is to identify novel biomarkers and pathways to advance early detection and personalized treatment.
El documento habla sobre la administración de blogs. Explica conceptos clave como entradas, categorías, etiquetas y páginas que son elementos fundamentales para organizar y estructurar el contenido de un blog. También describe brevemente las ventajas del uso de blogs y las licencias Creative Commons.
This file is about the best bridal makeup artist in chennai Mr.Vijay. he services for the bridal,betrothol,movies,Tv shows,adpromotions,school and college events.
Using liquid biopsies to study cancer dynamics and drug resistanceSpeck&Tech
Liquid biopsies, which analyze cell-free DNA in blood, can be used to study cancer evolution and drug resistance over time. By tracking genetic mutations in plasma samples taken at different time points, researchers can create a temporal map of how a tumor changes with and without treatment. This approach has identified biomarkers of drug resistance and shown that tumors with higher levels of circulating tumor DNA have worse outcomes and are less responsive to some therapies. While liquid biopsies hold promise for early cancer detection and precision medicine, more large clinical studies are still needed to validate their clinical utility.
`Liquid biopsy' using blood test is latest weapon against cancerOther Mother
Researchers are testing a new "liquid biopsy" using blood tests that can detect tiny fragments of cancer DNA shed by tumors into the bloodstream. This less invasive method shows promise in determining if treatments are working and could be used to continuously monitor patients. Early results found the liquid biopsy predicted cancer recurrences over 3 months before CT scans in some cases. Oncologists hope this method may allow more personalized and effective cancer monitoring and treatment in the future.
Liquid biopsy quality control – the importance of plasma quality, sample prep...Thermo Fisher Scientific
Liquid biopsy is emerging as a non-invasive companion to traditional solid tumor biopsies. As next generation sequencing (NGS) of circulating cell-free nucleic acids (cfNA = cfDNA and cfRNA) becomes common, it’s important to understand the impact of sample preparation on quality, specificity, and sensitivity of liquid biopsy tests. Plasma samples are often limited, and may have undesirable characteristics such as lipemia or hemolysis that contribute unwanted genomic DNA (gDNA) to the sample. Low cfDNA concentration can also limit the amount available for NGS library prep. In this study, we explore the effects of suboptimal plasma and low library input on liquid biopsy NGS, and discuss various techniques for in-process quality control of cfNA samples isolated from plasma
Newer diagnostic tools in oncology such as liquid biopsies provide non-invasive approaches to diagnosing and monitoring cancer. Liquid biopsies analyze biomarkers found in bodily fluids and can detect circulating tumor cells, circulating tumor DNA, RNA, and exosomes shed by tumors into the bloodstream. These liquid biomarkers offer advantages over traditional tissue biopsies by being less invasive, able to capture the heterogeneity of tumors, and allow for real-time monitoring of treatment response and disease progression. Emerging technologies now allow liquid biopsies to provide genomic information that can help classify and treat cancers based on their molecular profiles rather than the organ or tissue of origin.
An overview of circulating cell-free DNA (cfDNA) as liquid biopsy biomarkers and the role of circulating tumour DNA (ctDNA) in advancing cancer research and diagnosis through non-invasive tumour mutation profiling
The Molecular Analysis on Circulating Tumor Cells to Determine Prognostic and...QIAGEN
Circulating tumor cells (CTCs) is an emerging source used molecular cancer diagnostics. Through expression profiling of CTCs, it allows a deeper understanding about which metabolic pathways enable tumor cells to survive in the circulation, how they become resistant to a drug regimen, how they transform and adapt and, finally, which cellular markers should targeted for future therapies.
This webinar will introduce the AdnaTest CTC detection platform which has been proven in several clinical trials to provide prognostic and predictive information in breast, ovarian and prostate cancer. The platform by itself is still open for research and allows access to any potential target of interest. Join us to learn more about this novel platform, its technology and applications in liquid biopsy.
This study aimed to develop an unbiased RNA profiling approach for the early detection of colorectal cancer (CRC) and advanced adenomas (AA) using blood samples. The researchers combined a literature review with microarray analysis of circulating RNA purified from plasma to identify RNA biomarker panels. They tested the panels on two cohorts, detecting CRC with 75% sensitivity and 93% specificity using an 8-gene panel, and detecting AA with 60% sensitivity and 87% specificity using a 2-gene panel. The study demonstrates the feasibility of unbiased molecular diagnosis of CRC and AA from blood and introduces circulating RNA profiling as a potential non-invasive screening approach.
This document discusses various minimally invasive interventions for liver tumors. It describes procedures such as transarterial chemoembolization (TACE), radiofrequency ablation (RFA), microwave ablation, cryoablation, ethanol ablation, and drug-eluting bead chemoembolization. For each procedure, it covers the mechanism of action, patient selection criteria, technical details, imaging guidance and follow up. It emphasizes that these minimally invasive therapies can be used to treat primary and secondary liver malignancies when surgery is not possible or as an adjunct to other treatments, with the aim of improving patient prognosis.
This document discusses tumor markers and their use in monitoring tumor response to therapy. It provides information on different types of tumor markers including proteins, enzymes, hormones, genetic markers and circulating tumor cells. Ideal tumor markers are highly sensitive and specific, correlate with tumor stage and prognosis, and can be used for screening, diagnosis, prognosis, monitoring treatment and detecting recurrence. Examples discussed include CEA, AFP, PSA, CA125 and circulating tumor cells. The Oncotype DX 21-gene recurrence score test and tissue polypeptide specific antigen are also summarized.
Surgery plays an important role in treating metastatic colorectal cancer. The document discusses:
1) The liver is the most common site of metastasis and surgical resection of isolated liver metastases can provide a 5-year survival rate of 45-60%, compared to just 6-9 months with no treatment.
2) Other potentially resectable isolated metastases, such as those in the lungs or peritoneum, may also be treated with surgery, providing 5-year survival rates around 20-40%.
3) Neoadjuvant chemotherapy can downsize initially unresectable liver metastases to make them resectable and improve long-term outcomes compared to surgery alone.
A tumor marker is a substance present in or produced by a tumor or by the tumor’s host in response to the tumor’s presence that can be used to differentiate a tumor from normal tissue or to determine the presence of a tumor based on measurement in the blood or secretions.
Maintrac liquid biopsy allows quantitative detection of circulating tumor cells without fixation, isolation, or enrichment. It uses fluorochrome-labeled antibody targeting EpCAM antigen on circulating tumor cells. In contrast, Cellsearch uses fixation and enrichment procedures that lead to loss of cells and antigenicity, resulting in dead cells. Comparison of the two methods using the same blood sample from a patient showed Maintrac detected more total events and circulating tumor cells than Cellsearch. Other CTC detection technologies have limitations such as relying too heavily on EpCAM expression or assuming CTCs are larger than blood cells. Cell-free tumor DNA analysis has problems like representing destroyed cells and additional mutations from DNA degradation.
Chapter 2.3 tumor biomarkers and vascular accessNilesh Kucha
This document discusses various tumor biomarkers, including what they are, their clinical uses, and specifics about common biomarkers like AFP, CA125, CA19-9, CA15-3, CEA, hCG, and PSA. It provides details on what types of cancers and conditions can cause elevations, reference ranges, half-lives, and how they are used for screening, diagnosis, prognosis, prediction, and monitoring of cancers. Ideal biomarkers are defined as highly specific and sensitive, correlating with tumor viability, reproducible, cheap, and detectable in occult disease.
The document discusses circulating tumor cells (CTCs) and their clinical applications. It summarizes the work of Brian Kirby's research group, which works at the interface of microfluidics, microtechnology, and cellular analysis. The group has developed a technique called GEDI (Geometrically Enhanced Differential Immunocapture) to isolate CTCs from blood samples. GEDI leverages fluid mechanical design and size-dependent interactions to maximize capture of rare CTCs while eliminating leukocytes. The group has used captured CTCs from castrate-resistant prostate cancer patients to functionally evaluate drug responses by examining markers like tubulin bundling and nuclear accumulation of the androgen receptor. They are currently conducting the
management of metastatic colorectal cancer Sujay Susikar
1) Metastatic colorectal cancer presents significant challenges, as around 40% of patients initially present with metastatic disease and 50% of those initially diagnosed without metastases will eventually develop them.
2) Management depends on whether metastases are synchronous or metachronous. For potentially resectable metastases, surgical resection offers the best chance of cure, with 5-year survival rates of 24-58% after resection of liver metastases.
3) For unresectable metastases, options include ablation techniques like radiofrequency ablation or cryotherapy, regional therapies like chemoembolization, systemic chemotherapy, and targeted agents. The goal is conversion to resectability with chemotherapy when possible.
Pancreatic cancer has a high mortality rate because it is often diagnosed late after metastasizing. Early detection is difficult because symptoms usually do not appear until it has spread. This paper aims to integrate multi-omic data like genomics, proteomics, and imaging into a predictive model to better classify pancreatic cancer patients. The goal is to identify novel biomarkers and pathways to advance early detection and personalized treatment.
El documento habla sobre la administración de blogs. Explica conceptos clave como entradas, categorías, etiquetas y páginas que son elementos fundamentales para organizar y estructurar el contenido de un blog. También describe brevemente las ventajas del uso de blogs y las licencias Creative Commons.
This file is about the best bridal makeup artist in chennai Mr.Vijay. he services for the bridal,betrothol,movies,Tv shows,adpromotions,school and college events.
Inovio is developing powerful DNA-based immunotherapy and vaccine platforms. They have shown clinical proof of concept for treating pre-cancerous conditions and generating antigen-specific CD8+ T cells in vivo. Their lead product VGX-3100 has achieved efficacy endpoints in a phase II cervical dysplasia trial and will enter phase III in 2016. Inovio is pursuing both monotherapy and combination approaches for cancer as well as partnerships with AstraZeneca and others. They have a broad pipeline of products in clinical trials for cancer and infectious diseases.
Netwealth educational webinar - Lessons from Silicon Valley and what it means...netwealthInvest
This document summarizes a presentation by Santi Burridge on lessons from Silicon Valley for Australian financial advisers. Key points include:
- Over 800 startups in Silicon Valley are focused on financial services and know more about clients than advisers.
- Advisers' role in investment advice is changing due to technology enabling mass customization of advice.
- Australian advisers need to embrace technology to ensure future disruption complements their businesses.
- Advisers should focus on building scalable, personalized client experiences through technology.
Pensando dessa forma cada vez mais, o Canal Rural quer relacionar grandes e mais marcas ao maior projeto de soja brasileiro, gerando visibilidade nas ações de plantio e colheita, da mesma forma que faz com patrocinadores do Soja Brasil.
El documento discute los hallazgos de investigadores sobre la adicción a Internet entre los jóvenes, incluyendo que la mayoría pasa más de 10 horas al día en Internet y se sienten incapaces de vivir sin ella. Los investigadores realizaron un experimento donde los jóvenes no tenían acceso a Internet y expresaron ansiedad, depresión y sentimientos negativos como resultado. También encontraron que los jóvenes prefieren pasar tiempo en Internet en lugar de estudiar y que algunos visitan sitios inadecuados.
PEGS Europe Protein & Antibody Engineering Summit 2014 AgendaNicole Proulx
PEGS Europe is the largest European event covering all aspects of protein and antibody engineering. With two consecutive years of 40% growth in attendance, and another year of expanded program coverage, this year’s event will feature:
•500 attendees
•150 technical presentations
•70+ scientific posters
•40+ sponsors & exhibitors
•Dedicated networking opportunities
•Exclusive exhibit & poster hours
•Interactive roundtable, breakout & panel discussions
Sadarbība ar Centrālo finanšu un līgumu aģentūru jaunajā plānošanas periodāEkonomikas ministrija
Sadarbība ar Centrālo finanšu un līgumu aģentūru jaunajā plānošanas periodā
Anita Beke, Centrālā Finanšu un līgumu aģentūra
2014.gada 25.novembris, Liepāja
This document provides information about an elective course on teaching English for specific purposes. The purpose of the course is to help teachers reflect critically on their pedagogical practices and develop their own ideas for teaching and materials development through research articles and exercises. The general skills covered in the course include comparing study techniques and previous research approaches, developing critical analyses of academic discourse in relevant subject areas, and creating teaching materials for native and non-native English speakers based on communication skills needed in academic settings.
Latvijas Investīciju un attīstības aģentūras pakalpojumi uzņēmējiemEkonomikas ministrija
Latvijas Investīciju un attīstības aģentūras pakalpojumi uzņēmējiem
Linda Grīnfelde, Latvijas Investīciju un attīstības aģentūra
2015.gada 27.oktobris, Jēkabpils
Last week I gave another PhD progress report at ZGIS' PhD seminar. I showed a couple of preliminary results of a study I'm planning to publish in spring 2016.
Suggestions, comments and questions are highly welcome at this stage.
Mahabaratham by Valangaiman Kutty rajesh(Chinnatrangarai)sakkara123
The document discusses the historicity of events described in the Mahabharata epic. It notes there are two divergent views - some see it as completely historical while others view it as fictional. The author conducted excavations at key sites like Hastinapura and found archaeological evidence from the Painted Grey Ware culture period that corroborates details from the texts. Based on textual references and averaging reign lengths, the author estimates the date of the Mahabharata war to around 900 BCE, though some date it as early as 3102 BCE based on astronomical data in the texts.
Extracellular Biomarkers Summit, the newest addition to Cambridge Healthtech Institute's notable biomarker and diagnostics portfolio, merges the well-established microRNA as Biomarkers and Diagnostics Conference with focused discussions on three leading areas of research: the role of circulating microRNA, exosomes and microvesicles, long non-coding RNA and extracellular RNA in cancer and other diseases, as well as their potential to serve as biomarkers in drug and diagnostic development. Discussions will include the isolation and characterization of exosomes and exRNA, including expression profiling and sequencing of exRNA; understanding the role of miRNA, lncRNA, and exosomes in disease mechanism, tumor metastasis, and intracellular communication; their potential as biomarkers in drug development, drug toxicity assessment, and patient stratification; and finally, their role as circulating biomarkers for disease diagnosis and prognosis. Learn more at http://www.extracellularbiomarkers.com
Join us in Boston this coming Fall to attend Cambridge Healthtech Institute's (CHI) 2nd Annual FAST: Functional Analysis & Screening Technologies Congress on November 17-19, 2014 and meet with a community of 250+ biologists, screening managers, assay developers, engineers and pharmacologists dedicated to improving in vitro cell models and phenotypic screening to advance drug discovery and development at 6 conferences: Phenotypic Drug Discovery (Part I & II), Engineering Functional 3D Models, Screening and Functional Analysis of 3D Models, Organotypic Culture Models for Toxicology and Physiologically-Relevant Cellular Tumor Models for Drug Discovery. Delegates have the opportunity to share insights in interactive panel discussions and connect during networking breaks. View innovative technologies and scientific research revolutionizing early-stage drug discovery in the exhibit/poster hall.
5th Tumor Models Boston July 2017 BrochureDiane McKenna
Tumor Models Boston 2017 will address the preclinical & clinical developments of the most promising therapies including targeted therapies, check-point inhibitors & CAR-T therapies and how these findings can be utilized to bridge the gap between preclinical and clinical studies.
Attracting over 3,300 drug discovery and development professionals from over 40 countries in 2015, the Tri-Conference has grown into a diverse event, focusing on Molecular Medicine, specifically on Discovery, Genomics, Diagnostics and Information Technology.
With a 23 year history, this year’s expanded coverage includes additional programs on Molecular Diagnostics for Infectious Disease, Precision Medicine and Cancer Immunotherapy, as well as two new symposia on Companion Diagnostics and the Commercialization of Molecular Diagnostics.
TCGC The Clinical Genome Conference 2015Nicole Proulx
Bio-IT World and Cambridge Healthtech Institute are again proud to host the Fourth Annual TCGC: The Clinical Genome Conference, inviting stakeholders impacting clinical genomics to share new findings and solutions for advancing the applications of clinical genome medicine.
SMi Group's 8th annual Advances in Cell Based AssaysDale Butler
This document provides information about two half-day post-conference workshops on November 12, 2015 following the Advances in Cell Based Assays conference on November 10-11, 2015. Workshop A will focus on the latest generation microscopes for live cell imaging in high-throughput, high-content, and high-content analytical assays, featuring an interactive session with Nikon, UK. Workshop B will explore applying tissue engineering to develop 3D cell-based assays, focusing on generating in vitro disease models, led by Associate Professor Felicity Rose. Both workshops aim to discuss cutting-edge technologies and their applications to advance cell and tissue-based screening assays.
This document provides information about two half-day post-conference workshops on November 12, 2015 following the Advances in Cell Based Assays conference on November 10-11, 2015. Workshop A will focus on the latest generation microscopes for live cell imaging in high-throughput, high-content, and high-content analytical assays, featuring an interactive session with Nikon, UK. Workshop B will explore applying tissue engineering to develop 3D cell-based assays, focusing on generating in vitro disease models, led by Associate Professor Felicity Rose. Both workshops aim to discuss cutting-edge technologies and their applications to advance cell and tissue-based screening assays.
This document provides information about the "BioData World West 2017" conference taking place April 26-27, 2017 in San Francisco. The conference will bring together over 200 participants from various backgrounds to discuss disruptive approaches in drug development, personalized medicine, and clinical applications using big data in precision medicine. Expert speakers will present on topics including genomics, precision medicine, and a new AI track in partnership with Merck. Registering online reserves a place at the conference and featured sessions will explore various applications and challenges of harnessing big data in healthcare and biomedicine.
Advancing Convergence and Innovation in Cancer Research: Seminar at Universit...Jerry Lee
Since 2003, the National Cancer Institute’s Center for Strategic Scientific Initiatives (CSSI) has worked to develop the resources and infrastructures investigators need to surmount roadblocks in cancer research. CSSI manages programs that promote technology development and cross-disciplinary collaboration and provide support for investigators in nascent and challenging research fields. This support includes funding opportunities, shared reagent and database resources, and assistance in the development of standards and protocols. CSSI also provides a network of partners in industry and government that can help NCI-funded researchers advance their technologies toward commercialization and translation. This presentation will highlight technologies including single-cell isolation and analysis techniques that have been supported through various CSSI mechanisms from proof-of-concept to translation into the clinic.
This document summarizes an upcoming Cancer Diagnosis & Therapy Congress organized by MnM Conferences on September 3-4, 2015 in London. The two-day conference will bring over 150 experts from around the world to discuss advances in cancer diagnosis technologies and novel targeted cancer therapies. Key discussion topics will include interventional radiology techniques, immunotherapy, biomarkers, nanotechnology, biosensors, and functional genomics. Over 30 distinguished international speakers will present, including researchers from industry, academia, and hospitals. The conference aims to provide a platform for knowledge sharing between researchers, pharmaceutical companies, and doctors to collaborate and stay updated on the latest discoveries and technologies for cancer diagnosis and treatment.
This document provides an agenda and program details for a symposium on advances in childhood cancer hosted by Kids Cancer Alliance (KCA). The free event will be held on August 31, 2018 at the Australian National Maritime Museum and will feature talks on topics such as clinical application of whole genome sequencing, analysis of big data in pediatric cancers, cancer epigenetics, immunotherapies including CAR T cell therapy, and high dimensional analysis of single cell proteome data. Speakers include researchers from Australia, the US, and Switzerland with expertise in areas like cancer genomics, bioinformatics, immunology, and data science.
Oncology Discoveries, University of Chicagouchicagotech
The University of Chicago Comprehensive Cancer Center (UCCCC) uses cooperative, multidisciplinary initiatives to support innovative cancer research. It has over 320 active clinical trials spanning various phases, as well as core facilities that support research efforts. Research is organized into six scientific programs, including Molecular Mechanisms of Cancer and Hematopoiesis and Hematological Malignancies. These programs work to define the genetic causes of cancer and develop targeted therapies through translational research that moves between basic science and clinical applications. Representative technologies described include methods for inhibiting cancer metastasis and developing novel antibodies.
American Association for Cancer Research Annual Meeting 2022
Analysis of images of routinely acquired tissue specimens promise to provide biomarkers that can be used to predict disease outcome and steer treatment, improve diagnostic reproducibility, and reveal new insights to further advance current human understanding of disease. The advent of AI and ubiquitous high-end computing are making it possible to carry out accurate whole slide image morphological and molecular tissue analyses at cellular and subcellular resolutions. AI methods are can enable exploration and discovery of novel diagnostic biomarkers grounded in prognostically predictive spatial and molecular patterns as well as quantitative assessments of predictive value and reproducibility of traditional morphological patterns employed in anatomic pathology. AI methods may be adapted to help steer treatment through integrative analysis of clinical information along with Pathology, Radiology and molecular data.
Advancing The Prevention And Cure Of Cancerfondas vakalis
The document discusses the shared missions and collaborations between the American Association for Cancer Research (AACR) and the National Cancer Institute (NCI) to advance cancer research and reduce the burden of cancer. It outlines their joint efforts in conferences, workshops, and think tanks. It also summarizes advances in cancer prevention, early detection, and treatment that have contributed to reduced cancer mortality rates in recent years but challenges remain.
Researchers have developed new diagnostic techniques using digital PCR that can detect rare cancer cells or bacteria. For liver cancer, digital PCR analysis of circulating tumor cells found higher levels of cancer-associated RNA in patients compared to controls, allowing earlier diagnosis. A separate study used digital PCR to detect an enzyme from fecal indicator bacteria, creating simple tests to identify foodborne pathogens within hours. These advances may enable earlier detection of diseases before symptoms appear.
Global liquid biopsy market opportunity & technology outlook 2020Rajesh Sarma
Global Liquid Biopsy Market Opportunity & Technology Outlook 2020 provides an overview of the liquid biopsy market. Liquid biopsy is a non-invasive method that analyzes blood or other bodily fluids to detect biomarkers associated with cancer and other diseases. It has three main techniques - analysis of circulating tumor cells, cell-free tumor DNA, and exosomes. Next generation sequencing is also used to analyze genomic and proteomic sequences from tumor cells captured in liquid biopsies. The report examines the clinical uses and advantages of liquid biopsy compared to traditional tissue biopsy for various cancer types and other indications. It also discusses market drivers and trends, as well as challenges, for the growing liquid biopsy industry.
This presentation by Pressure BioSciences discusses their Pressure Cycling Technology platform for biological sample preparation. Some key points:
- PCT uses ultra-high pressure to break up cell walls and extract biomolecules, achieving better results than mechanical methods.
- The market for biological sample preparation is multi-billion dollars. PCT addresses the need for improved sample prep methods.
- Over 275 PCT systems have been installed at over 150 customer sites. There are over 100 publications highlighting PCT's advantages.
- Recent accomplishments include a co-marketing agreement with SCIEX, a leader in analytical technologies, and sales of their new Barocycler 2320EXTREME system.
SMi Group's 7th annual Advances in Cell Based Assays conferenceDale Butler
This document summarizes a two-day conference on advances in cell-based assays being held on November 11-12, 2014 in London. The conference will explore the latest developments in cell-based assays and their application in drug discovery and development. Speakers will include representatives from pharmaceutical companies such as GSK, AstraZeneca, Novartis, UCB, and Merck Serono, as well as academics. Topics will include the use of cell-based assays in biologics drug discovery, challenges in validation and regulation, phenotypic screening, stem cell technologies, and 3D cell cultures. Workshops on leveraging cell-based assays for open innovation and evaluating cell-based assays in drug discovery will also be offered
CHI's Bioassays for Immuno-Oncology Symposium, Oct. 23, 2017 in Washington, DCJames Prudhomme
Biological assays demonstrating drug characteristics such as potency, mechanism-of-action, and stability, are one of the most critical components of an FDA biologic submission. However, with more complex mechanisms-of-action, immunotherapies add a layer of difficulty to bioassay selection and development. At Cambridge Healthtech Institute's Inaugural Bioassays for Immuno-Oncology symposium, experts in bioassays for immuno-oncology therapies will discuss selection, development, and standards for bioassays and immunoassays. Special attention will be given to understanding the mechanism-of-action for immunotherapies, whether they be antibody- or cell-based. Overall, this one-day immersive symposium will outline a product life cycle approach for developing and implementing biological assays from preclinical studies to clinical development. This symposium is part of the Immunogenicity & Bioassay Summit.
Similar to The Liquid Biopsy Summit Brochure 2016 (20)
PEGS Boston the essential protein engineering summitNicole Proulx
With record-breaking attendance in 2015, PEGS Boston attracts an international delegation of nearly 2,000 participants including conference delegates, speakers, exhibitors, sponsors and guests representing over 30 countries.
Participants value the in-depth short courses, access to 22 conferences, and wide-ranging presentations delivering new unpublished data, case studies, innovation and insight.
The vast exhibit hall will be packed with 125 exhibiting companies and more than 200 research posters on display providing valuable viewing of innovative new technologies, as well as abundant networking with biopharma researchers and industry representatives.
In its third year, “PEGS China: Protein and Antibody Engineering & Development Summit” returns to Shanghai for 3 days of inspiring presentations and case studies featuring the latest trends and future potential of China’s biotech industry.
This year’s event comprises four content-driven conferences with over sixty global speakers, plus a new 1-day seminar on clinical & regulatory strategies for global and domestic IND and BLA filings. In addition, dedicated exhibit hall and poster viewing hours will provide invaluable opportunities for networking, deal-making and ideas exchange.
PepTalk: The Protein Science Week is an annual gathering where industry experts from around the world convene to share case studies, unpublished data, breakthroughs and solutions that support and enhance research, and to gain new perspectives on the evolution of biologics.
Pegs Europe 2015 Protein & Antibody Engineering SummitNicole Proulx
PEGS Europe is the largest European event covering all aspects of protein and antibody engineering. With three consecutive years of 35% growth in attendance, and another year of expanded program coverage, this year’s event will feature:
700 attendees
175 technical presentations
125 scientific posters
Dedicated networking opportunities
Exclusive exhibit & poster viewing hours
Interactive roundtable, breakout & panel discussions
PEGS Korea 2015 the essential protein engineering summitNicole Proulx
PEGS is Cambridge Healthtech institute (CHI)’s flagship biologics meeting, and is widely considered the industry’s leading event on protein and antibody engineering. Its successful accolades include an annual attendance of over 1800 participants at the PEGS Summit in Boston; a record attendance of over 500 attendees at PEGS Europe this year; a successful launch of PEGS China in 2014, and now, the announcement of the first PEGS Korea to be launched in September 2015.
The 3-day Inaugural PEGS Korea will bring together an international faculty consisting of scientists, engineers and executives from all over the world to share their expertise and experiences in protein and antibody engineering, particularly in developing next-generation therapeutics including ADCs, bispecifics, and immunomodulating antibodies.
The 2015 Bioprocessing Summit plans to unite 750+ attendees from 30+ countries for five days of inspiring presentations and solutions. The Bioprocessing Summit brings together international leaders to discuss today's bioprocess issues from cell line selection to manufacturing. The Summit provides practical details in a relaxed, congenial atmosphere that promotes information exchange and networking.
This leading bioprocess meeting is hosted in Boston each summer. Hundreds of bioprocess professionals come together each year at the Summit to share practical solutions for today’s bioprocess challenges with researchers from around the world.
Spanning five days, the 2015 meeting includes 12 conference programs, 8 training seminars and 10 short courses.
World Preclinical Congress 2015 BrochureNicole Proulx
The World Preclinical Congress (WPC; formerly the
World Pharma Congress), now in its 14th year, is making
a commitment to focus predominantly on preclinical
research and highlight the challenges and opportunities
in early drug discovery and development. World
Preclinical Congress 2015 brings together some of
the hottest topics being discussed in the pharma/
biotech world and provides a unique forum for scientists
and clinicians to exchange ideas and collaborate to
overcome some of the translational challenges. This
coincides with the event moving to Boston, now a
premier hub for preclinical activity and alliances.
PEGS the essential protein and antibody engineering summit Nicole Proulx
PEGS - The Essential Protein Engineering Summit is the premier event for antibody and protein science research and the biologics industry, with more than 1,800 participants in attendance from over 30 countries. Join us in Boston this May 4-8, 2015 to share insights and best practices with colleagues, connect and form new collaborations during copious networking opportunities, learn from world-renowned thought leaders, discover industry trends and find solutions to current challenges. PEGS is knowledge-sharing at its best.
This 3-day event is the meeting place for international and domestic scientists to share case studies and project updates, showcase new techniques and form collaborations that pave the way towards the future of China’s biopharmaceutical industry.
12th Annual Molecular Diagnostics Conference Part of TRI-CON 2015Nicole Proulx
CHI's flagship diagnostics event, "Molecular Diagnostics: Executive Strategies for Success" taking place February 16-18, 2015 in San Francisco, CA. In its twelfth year this is the leading event for the industry featuring experts on business strategy, platform development, regulation and reimbursement who will outline the steps needed to take to achieve commercial success in the current environment.
The document summarizes the 14th Annual PepTalk conference organized by Cambridge Healthtech Institute. The conference will be held from January 19-23, 2015 in San Diego, CA and will feature over 1,200 international participants from industry, academia and government. It will include 20 conferences, 13 short courses, 325 speaker presentations, 80 roundtable discussions, 100 exhibitors and 125 research posters on topics related to protein engineering, antibody therapeutics, formulation, production, analytics and purification. A keynote speech will be given by Dr. John Yates from The Scripps Research Institute on advances in proteomics. The conference provides numerous opportunities for education, innovation and networking in the protein science field.
This year's 3rd Annual TCGC: The Clinical Genome Conference, held June 10-12, 2014 in San Francisco, is a three-day event that weaves together the science of sequencing and the business of implementing genomics in the clinic. It uniquely illustrates the mutual influence of those areas and the need to therefore consider the needs, challenges and opportunities of both - from next-generation sequencing and variant interpretation to insurance reimbursement and electronic health records - throughout the entire research process.Learn more at http://www.clinicalgenomeconference.com
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...rightmanforbloodline
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
The Liquid Biopsy Summit Brochure 2016
1. LIQUIDBIOPSYSUMMIT.COM
Keynote Speakers
Ellen M. Beasley, Ph.D.,
Senior Vice President,
Product & Services
Research & Development,
Business &
Product Development,
Genomic Health, Inc.
Steven A. Soper, Ph.D.,
Professor, Biomedical
Engineering & Chemistry;
Associate Editor, Analyst;
Director, Center for
BioModular Multiscale
Systems, University of North Carolina
MuneeshTewari, M.D.,
Ph.D., Associate Professor,
Internal Medicine and
Biomedical Engineering &
Ray and Ruth Anderson-
Laurence M. Sprague
Memorial Research Professor, University
of Michigan Health System
Symposium June 22
Circulating Markers in Cancer:
Tools for Identification, Evaluation andTranslation
Dinner Short Course June 23
Molecular Beacons; Stellaris FISH Probes; and
SuperSelective PCR Primers for Liquid Biopsies
Conference Sessions June 22 - 24
Oncology: Liquid Biopsies Are Advancing into the Clinic
Tools that Capture, Amplify and Analyze Minute
Amounts of Nucleic Acids
Moving Beyond Cancer:Tackling OtherTargets
Detecting the Role of Extracellular RNAs in
Health and Disease
LIQUIDBIOPSY
SUMMIT
THE
JUNE 22 - 24, 2016
HOTEL KABUKI | SAN FRANCISCO, CALIFORNIA
Refining Circulating Cell-Free Tools and Technologies for Translational Research
final agenda
Register by March 18
Saveupto$
400
CORPORATE
SUPPORT
SPONSOR
CORPORATE
SPONSOR
Join your peers and colleagues in San Francisco
to gain insight and perspective on why molecular
liquid biopsies have the potential to become a
fulcrum in the future of precision medicine.
This is an unprecedented time in biomolecular
medicine. Recent scientific findings have determined
biofluids consist of circulating cell-free (cf)DNA and
extracellular (ex)RNA from multiple tissues within
the body. In addition, the rapid development of highly
sensitive and accurate next-generation sequencing
(NGS) technologies has empowered researchers
to analyze the role of these biomolecules in health,
disease and treatment response. However, there
remains considerable insecurity associated with
biofluid-based DNA/RNA analytical methods which
must be solved before liquid biopsies can be
implemented for broader routine applications.
2. 2 LIQUIDBIOPSYSUMMIT.COM
Present Your Research
Poster and Save $50!
Cambridge Healthtech Institute
encourages attendees to gain further
exposure by presenting their work
in the poster sessions. To secure
a poster board and inclusion in the
conference materials, your abstract
must be submitted, approved and your
registration paid in full by May 13, 2016
Reasons you should present your
research poster at this conference:
• Your poster will be seen by
our international delegation,
representing leaders from top
pharmaceutical, biotech, academic
and government institutions
• Receive $50 off your registration
• Your poster abstract will be published
in our conference materials
molecularbeacons;stellarisfish
probes;andsuperselectivepcr
primersforliquidbiopsies
dinnershortcourse*
THURSDAY, JUNE 23 | 5:45-8:45 PM
SC1: Molecular Beacons;Stellaris FISH Probes; and
SuperSelective PCR Primers for Liquid Biopsies
Instructors:
Fred Russell Kramer, Ph.D., Professor, Microbiology, Biochemistry and
Molecular Genetics, New Jersey Medical School, Rutgers University
Sanjay Tyagi, Ph.D., Professor, Medicine, Public Health Research Institute,
New Jersey Medical School, Rutgers University
Section 1: Finicky and Sloppy Molecular Beacons
Section 2: Imaging Single mRNA Molecules in Living and Fixed Cells
Section 3: Multiplex Real-Time PCR Assays that Assess the
Abundance of Extremely Rare Mutations Associated with Cancer
Please visit the conference website for a complete syllabus.
* Separate registration required
CORPORATE SUPPORT SPONSORCORPORATE SPONSOR
EVENT FEATURES
The Liquid Biopsy Summit is uniquely designed to provide
up-to-date coverage for this rapidly evolving field through:
Networking
• Breakout Discussion Groups
• Reception and Refreshment Breaks
One-on-One Discussions
• Poster Sessions
• Q&A following Presentations
• Solution Providers
In-Depth Coverage
• Symposium on current technologies for CTCs
and (cf)DNA
• Short Course on PCR: Probes, Primers, and Beacons
• Panel Discussion on current challenges and future
opportunities
• Identifying biofluid molecular markers (cf)DNA and
(ex)RNA from tissue
• Latest research from academic, biotech, and
established diagnostic companies
• Providing faster, cheaper, and less invasive biopsies
• Developing clinically actionable tests
• Expanding molecular targets and indications
• Combining liquid biopsies with personalized therapies
Unique Japantown Location
• Convenient location near many
San Francisco attractions
• Rich in Culture and Luxury
#LBS16STAY CONNECTED
3. LIQUIDBIOPSYSUMMIT.COM 3
WEDNESDAY, JUNE 22
7:30 am Symposium Registration and Morning Coffee
From CTCs to New Diagnostics
8:30 Organizer’s Opening Remarks
Mary Ann Brown, Executive Director, Conferences, Cambridge Healthtech Institute
8:35 Chairperson’s Opening Remarks
Lidia C. Sambucetti, Ph.D., Senior Director, Cancer Research Technologies,
SRI International Biosciences Division
»»8:45 KEYNOTE PRESENTATION: NewTools for
the Isolation of Circulating Markers: Microfluidic
Systems for the Analysis of Circulating Cells,
Cell-Free DNA and Exosomes
Steven A. Soper, Ph.D., Professor, Biomedical Engineering & Chemistry;
Associate Editor, Analyst; Director, Center for BioModular Multiscale
Systems, University of North Carolina
Liquid biopsies are generating interest within the biomedical community
due to the simplicity for securing important markers to realize precision
medicine. These circulating markers consist of whole cells such as CTCs,
molecules such as cell-free DNA and nanovesicles such as exosomes.
We are developing microfluidic systems that can process whole blood
directly and select all three of these markers from a single blood sample.
The devices can not only collect the markers from blood samples, but
also perform molecular analysis on their cargo.
9:15 OpticalTechnologies for CTC Analysis
Gregory Faris, Ph.D., Program Manager, Optical Systems, Discovery
Technologies, SRI International
This talk describes two technologies for CTC analysis. The first is a non-
enrichment method for selection of CTCs using optical imaging. The second
method uses laser heating for multiplexed in situ PCR and RT-PCR in nanoliter
droplets without removing cells.
9:45Trends in Automating CTC Capture: Progress towards a
Simple and Inexpensive Assay
Siddarth Rawal, M.D., COO, Circulogix Inc.; Clinical Research Associate, Miller
School of Medicine, University of Miami
Circulating tumor cells (CTC) have been regarded as important biomarkers for
cancer prognosis, monitoring treatment response and companion diagnostics to
assess efficacy of novel targeted drugs in development. However, the effective and
complete enrichment of these rare events from whole blood remains a non-trivial,
manual-intensive and expensive endeavor. Reliable automated technologies are
needed to provide a consistent and easy workflow to generate exciting discoveries.
10:15 Networking Coffee Break
10:45 CirculatingTumor Cells in the Peripheral Blood Decrease in
Numbers withTreatment in Patients with Various Carcinomas
Rebecca (Becky) Suttmann, MS, Senior Scientific Researcher, Oncology
Biomarker Development, Genentech, Inc.
We summarize findings of CTC enumeration utilizing the CellSearch® platform
for isolating and enumerating cells from nearly 10,000 fresh whole-blood samples
from cancer patients enrolled in 20 clinical trials conducted by Genentech over
four years. Incidence and changes in CTC number and presence of targeted
markers were measured. Evaluation of numerous patient samples across multiple
indications has provided an opportunity to assess utility of CTC analysis on the
CellSearch® platform in the context of clinical drug development.
11:15 Microfluidics-Based Biomarker Isolation and Analysis for
Cancer Detection from Blood Samples
Rolf Muller, Ph.D., CEO, BioFluidica, Inc.
BioFluidica has developed a comprehensive platform technology to isolate
and detect rare biomarkers in blood samples. The technology allows large-
volume, whole-blood processing with high biomarker recovery and purity.
The technology is based on microfluidic isolation technology and has been
clinically validated for six different cancer types. We focus on the detection of
minimal residual disease in acute myeloid leukemia patients using circulating
leukemic cells selected from blood.
11:45 Sponsored Presentation (Opportunity Available)
12:15 pm Session Break
12:30 Luncheon Presentation (Sponsorship Opportunity Available)
or Lunch onYour Own
1:00 Session Break
Big Data and Applications of Analysis of ctDNA
2:00 Chairperson’s Remarks
Lidia C. Sambucetti, Ph.D., Senior Director, Cancer Research Technologies, SRI
International Biosciences Division
2:05 Studying theTumor Microenvironment with Big Data
Dvir Aran, Ph.D., Research Scientist, Atul Butte Laboratory, Institute for
Computational Health Sciences, University of California, San Francisco
Public genomic data now offer the opportunity for bioinformaticians to study
the tumor microenvironment. I present a systematic pan-cancer analysis of
tumor purity, which demonstrates how “purity” significantly biases genomic
analyses. However, this also allows new opportunities to study the crosstalk
of the microenvironment with the cancer. I conclude with our recent advances
to dissect the microenvironment further.
2:35 Monitoring CirculatingTumor DNA to Assess
Chemotherapeutic Effectiveness
Timothy Butler, Research Scientist, Paul Spellman Laboratory, Knight Cancer
Institute, Oregon Health & Science University
Circulating-tumor DNA (ctDNA) analysis has the potential to improve how we
monitor and treat patients with cancer. In this study we utilize a hybrid-capture
approach to sensitively monitor the ctDNA of breast cancer patients before,
during, and after undergoing neoadjuvant chemotherapy. Our findings offer
interesting insights into patient responses to neoadjuvant chemotherapy, and
may improve prognostic and treatment decisions following therapy.
3:05 Sponsored Presentation (Opportunity Available)
3:20 Networking Refreshment Break
3:45 Liquid Biopsy in Prostate Cancer
John S. Witte, Ph.D., Professor and Head, Division of Genetic and Cancer
Epidemiology; Associate Director, Institute for Human Genetics; Co-Leader,
Cancer Center Program in Cancer Genetics, University of California, San Francisco
4:15 Liquid Biopsies – Pushing the Envelope
Pamela Paris, Ph.D., Professor of Urology, Department of Urology, University
of California, San Francisco
4:45 PANEL DISCUSSION: Current and Future Applications of
Liquid Biopsies in Cancer
All agree CTCs and ctDNA are prognostic and predictive biomarkers
for cancer. However, different approaches for CTCs/ctDNA detection
and analysis to identify these tumor cell subpopulations need technical
standardization before their clinical validity and biological specificity may
be adequately investigated. Join these panelists as they discuss the
current challenges and future opportunities for liquid biopsies.
Panelists:
Ellen M. Beasley, Ph.D., Genomic Health, Inc.
Geoff Otto, Ph.D., Foundation Medicine
Steven A. Soper, Ph.D., University of North Carolina
Rebecca (Becky) Suttmann, MS, Genentech, Inc.
John S. Witte, Ph.D., University of California, San Francisco
5:30 Welcome Reception in the Exhibit Hall
with Poster Viewing
6:30 Close of Day
circulatingMarkersincancer:Tools for Identification, Evaluation and Translation
symposium
4. 4 LIQUIDBIOPSYSUMMIT.COM
WEDNESDAY, JUNE 22
3:45 pm Main Conference Registration
4:45 PANEL DISCUSSION: Current and Future Applications
of Liquid Biopsies in Cancer
All agree CTCs and ctDNA are prognostic and predictive biomarkers
for cancer. However, different approaches for CTCs/ctDNA detection
and analysis to identify these tumor cell subpopulations need technical
standardization before their clinical validity and biological specificity may
be adequately investigated. Join these panelists as they discuss the
current challenges and future opportunities for liquid biopsies.
Panelists:
Ellen M. Beasley, Ph.D., Genomic Health, Inc.
Geoff Otto, Ph.D., Foundation Medicine
Steven A. Soper, Ph.D., University of North Carolina
Rebecca (Becky) Suttmann, MS, Genentech, Inc.
John S. Witte, Ph.D., University of California, San Francisco
5:30 Welcome Reception in the Exhibit Hall
with Poster Viewing
6:30 Close of Day
THURSDAY, JUNE 23
8:00 am Morning Coffee
Oncology: Liquid Biopsies Are Advancing into the Clinic
8:30 Organizer’s Opening Remarks
Mary Ann Brown, Executive Director, Conferences, Cambridge Healthtech Institute
8:35 Chairperson’s Opening Remarks
Jamie Platt, Ph.D., MB(ASCP), Molecular Pathology Laboratory Network
»»8:45 KEYNOTE PRESENTATION: Liquid Biopsies in
Cancer Disease Management
Ellen M. Beasley, Ph.D., Senior Vice President, Product & Services Research
& Development, Business & Product Development, Genomic Health, Inc.
Liquid biopsies can be used to monitor tumor dynamics including
recurrence, or to profile individual genetic and genomic markers that
are informative of treatment options.Together, these complementary
approaches provide precision solutions to help manage disease along the
patient cancer journey.These also call for different development, analytical
and clinical validation strategies, as well as demonstration of clinical utility.
9:30 Circulating RNAs as Noninvasive Biomarkers in Colorectal
Cancer
Ajay Goel, Ph.D., Investigator/Professor & Director, Center for Gastrointestinal
Research; Director, Center for Epigenetics, Cancer Prevention and Cancer
Genomics, Baylor Research Institute and Charles A. Sammons Cancer Center,
Baylor University Medical Center
Given their cancer-specific pattern of expression, remarkable stability and
presence in blood and other body fluids, noncoding RNAs (ncRNAs) are
considered to be highly promising “liquid biopsy” cancer biomarkers.
Accumulating evidence firmly supports the existence of unique “ncRNA
signatures” that can not only facilitate earlier detection of the tumor, but
can also assist in predicting disease recurrence and therapeutic outcome to
current treatment regimens.
10:00 Accessing Genetic Information with Liquid Biopsies
Jian-Bing Fan, Ph.D., CEO, AnchorDx Corp.
The molecular liquid biopsies approach provides non-invasive access to
genetic information – somatic mutations, epigenetic changes, and differential
expression – about the physiological conditions of our body and diseases.
With the rapid development of highly sensitive and accurate technologies
such as next-generation sequencing, it is now possible to reliably analyze
CTCs and circulating nucleic acids in a clinic setting, which opens a valuable
avenue for future genetic studies and human disease diagnosis.
10:30 Coffee Break in the Exhibit Hall with Poster Viewing
11:00 Analytic Validation of an NGS-Based Clinical ctDNA Assay
Geoff Otto, Ph.D., Senior Director, Molecular Biology & Sequencing,
Foundation Medicine
Profiling circulating tumor DNA (ctDNA) for the genomic alterations (GA)
driving oncogenesis promises to provide insight into cancer biology, inform
therapy selection when conventional biopsies are unobtainable and enable
monitoring of response to therapy. A clinical, NGS-based ctDNA assay was
developed, highly accurate detection of GA was analytically validated and
clinical utility investigated from patient-matched FFPE and blood samples
across lung, breast and colon cancer at different disease stages.
11:30 Nucleosome Footprints in Cell-Free DNA Are Evidence of
ItsTissues of Origin
Andrew Hill, Graduate Research Fellow, Jay Shendure Laboratory, Genome
Sciences, University of Washington
Nucleosome positioning varies across cell types. Some proportion of cell-
free DNA (cfDNA) is protected by nucleosomes, which in principle could
allow detection of cell types contributing to cfDNA. We infer nucleosome
positioning in cfDNA to identify abnormal contributions in pathologies such as
cancer. Because this method does not rely on genetic differences between
healthy and pathological contributions, it could potentially broaden the scope
of cfDNA-based monitoring and diagnostics.
12:00 pm Presentation to be Announced Sponsored by
12:15 Sponsored Presentation
(Opportunity Available)
12:30 Session Break
12:45 Luncheon Presentation (Sponsorship Opportunity Available)
or Lunch onYour Own
1:15 Session Break
Tools that Capture, Amplify and Analyze Minute
Amounts of Nucleic Acids
2:00 Chairperson’s Remarks
Ellen M. Beasley, Ph.D., Genomic Health, Inc.
2:05 Nanocarbon-Coated Porous Anodic Alumina for Biological
Applications
Steven Prawer, Ph.D., D.Sc., Professor of Physics, School of Physics,
University of Melbourne
Here we demonstrate a new broad-range sensor platform for ultrasensitive
and selective detection of circulating DNA down to the single-molecule level.
The biosensor is based on a chemically functionalized nanoporous diamond-like
carbon (DLC)-coated alumina membrane.The few nanometer-thick, yet perfect
and continuous DLC coating confers the chemical stability and biocompatibility
of the sensor, allowing its direct application in biological conditions.
liquidbiopsysummitTHE
Conference Agenda
5. LIQUIDBIOPSYSUMMIT.COM 5
2:35T Oligo-Primed Polymerase Chain Reaction (TOP-PCR): A
Robust Method for the Amplification of Minute Amount of DNA
Fragments from Body Fluids
Kuo Ping Chiu, Ph.D., Associate Research Fellow, Genomics Research Center,
Academia Sinica
We have developedT oligo-primed PCR (TOP-PCR) for comprehensive
amplification of minute DNA fragments.TOP-PCR adopts homogeneous adaptor
(generated by P oligo andT oligo) for efficient ligation to A-tailed DNA, followed by
PCR amplification primed byT oligo. We demonstrate thatTOP-PCR maintains the
size profile of the DNA sample and is a superior method for recovering minute
DNA in body fluids. It maximizes the resolution of Illumina sequencing.
3:05 Sponsored Presentation (Opportunity Available)
3:20 Refreshment Break in the Exhibit Hall with Poster Viewing
4:00 Sample Prep in Genetic Assay Development
Toumy Guettouche, Ph.D., Director, Early Development & Genetics Assay
Development, Sequencing Unit, Roche Molecular Systems
4:30 Sample Prep in Liquid Biopsy; CanWe AlwaysWin the Lottery?
Jamie Platt, Ph.D., MB(ASCP), Vice President, Genomic Solutions, Molecular
Pathology Laboratory Network
The introduction of NGS has enabled some remarkable applications which allow for
less invasive specimen acquisition, and improved sensitivity and specificity. Liquid
biopsy is one application that holds enormous promise as a tool for monitoring
therapeutic response, detect residual disease, and even provide an earlier
diagnosis. However, one fact remains: you can’t detect what you haven’t sampled.
The key issues and opportunities for liquid biopsy sample prep will be discussed.
5:00 Next-Generation Liquid Biopsy:Tumor Monitoring from
Droplet Volumes of Blood
Chen-Hsiung Yeh, Ph.D., CSO, Circulogene Theranostics
Circulating cell-free DNA (cfDNA) can provide a global longitudinal picture of
tumor heterogeneity. Large sample volume, low yield, and labor intensiveness
are major obstacles for clinical application of cfDNA-based testing. Our
proprietary cfDNA sample preparation breakthrough enables clinicians to work
with a sample volume as small as 20 microliters (via a finger prick), which can
further expedite clinical decision-making and identify targeted therapies for
eligible patients in a time- and cost-efficient manner.
5:30 Close of Day and Short Course Registration
5:45-8:45 Dinner Short Course*
SC1: Molecular Beacons; Stellaris FISH Probes; and
SuperSelective PCR Primers for Liquid Biopsies
*Separate registration required. See page 2 for details.
FRIDAY, JUNE 24
7:30 am BREAKFAST BREAKOUT DISCUSSION GROUPS
Chew over breakfast and provocative discussion topics with your peers.These
are moderated discussions with brainstorming and interactive problem solving,
allowing conference participants from diverse backgrounds to exchange ideas
and experiences and develop future collaborations around a focused topic.
Standards of Evidence, Methods and Materials to Accelerate
Liquid Biopsy Development and Adoption
Moderator: Ellen M. Beasley, Ph.D., Genomic Health, Inc.
Taking ctDNA to the Clinic: Best Applications of Liquid Biopsies
to Improve CancerTreatment
Moderator: Timothy Butler, Oregon Health & Science University
Use of Systems or Computational Biology to Decipher the
Molecular Information that Arises from High-Throughput Liquid
Biopsies from the Plasma
Moderator: Stephen Y. Chan, M.D., Ph.D., University of Pittsburgh Medical
Center
NGS for Clinical Infectious Disease Diagnostics
Moderator: Charles Chiu, M.D., Ph.D., University of California, San Francisco
Nanoscience in the Service of BiologicalTechnologies
Moderator: Steven Prawer, Ph.D., D.Sc., University of Melbourne
Additional Breakout Discussion Groups to be Announced
Moving Beyond Cancer:Tackling OtherTargets
8:45 Chairperson’s Opening Remarks
Charles Chiu, M.D., Ph.D., University of California, San Francisco
8:50 Cell-Free DNA inTransplant Medicine
Kiran K. Khush, M.D., MAS, FACC, Associate Professor, Medicine, Division of
Cardiovascular Medicine, Stanford University School of Medicine
This talk reviews clinical applications of cell-free DNA testing in the field
of solid organ transplantation. Topics covered include (1) monitoring for
acute rejection, with illustrative cases from heart and lung transplantation,
(2) monitoring of the transplant recipients’ virome, and how it changes
with introduction and weaning of immunosuppression, and (3) non-biased
detection of disease-causing pathogens in transplant recipients.
9:20 Liquid Biopsy of the HIV Latent Reservoir in Patients on
Anti-RetroviralTherapies
Xiaohe Liu, Ph.D., Senior Scientist & Co-Leader, Rare Cell Technology
Program, Biosciences Division, SRI International
A major hurdle in HIV eradication research is the lack of robust assays to
characterize the reservoir cells that harbor HIV in the presence of anti-retroviral
therapy (ART). We applied FAST (Fiber-optic Array ScanningTechnology) to
detect and characterize rare cells that express HIV proteins in peripheral blood
of patients on ART. Our data suggest that FAST may be a new, important
method to identify and measure replication competent proviruses.
9:50 Metagenomic Next-Generation Sequencing for Diagnosis of
Infectious Diseases from Cell-Free Fluids
Charles Chiu, M.D., Ph.D., Associate Professor, Laboratory Medicine and
Medicine/Infectious Diseases; Director, UCSF-Abbott Viral Diagnostics and
Discovery Center; Associate Director, UCSF Clinical Microbiology Laboratory,
UCSF School of Medicine, University of California, San Francisco
Metagenomic next-generation sequencing (mNGS) is a powerful approach to
the diagnosis of infectious diseases, as it does not rely on targeted primers
or probes. A single sequencing test is able to identify all viruses, bacteria,
fungi, and parasites in clinical samples. Here we describe implementation
of a clinically validated mNGS assay from cerebrospinal fluid to diagnose
meningitis and encephalitis in critically ill hospitalized patients.
10:20 Sponsored Presentation (Opportunity Available)
10:35 Coffee Break in the Exhibit Hall with Poster Viewing
11:10 Looking for the Free Agents in Blood: High-Sensitivity RNA-
Seq Approaches for Detecting Infectious Agents in Liquid Biopsies
Andrew Brooks, Ph.D., COO, RUCDR Infinite Biologics; Associate Professor,
Genetics, Rutgers University
11:40 Using Immune Profiles to Categorize Neurological Disease
Nancy Monson, Ph.D., Associate Professor, Department of Neurology
and Neurotherapeutics & Department of Immunology, University of Texas
Southwestern Medical Center
Cerebrospinal fluid (CSF) samples have been a useful tool in the diagnosis
of neurological diseases involving the central nervous system (CNS). Our
laboratory has focused on finding new ways to use CSF as a diagnostic tool
for multiple sclerosis, an autoimmune disease of the CNS. We discovered that
antibody genetics of CSF-derived B cells can be used to identify patients who
have MS and patients who will develop MS in the future with 84-92% accuracy.
12:10 pm Sponsored Presentation (Opportunity Available)
12:40 Session Break
12:45 Luncheon Presentation (Sponsorship Opportunity Available)
or Lunch onYour Own
1:15 Session Break
6. 6 LIQUIDBIOPSYSUMMIT.COM
RECENT REPORT AVAILABLE FROM INSIGHT PHARMA REPORTS
Detecting the Role of Extracellular RNAs in Health
and Disease
2:00 Chairperson’s Remarks
Lynne T. Bemis, Ph.D., University of Minnesota
»»2:05 KEYNOTE PRESENTATION: Circulating
Extracellular RNAs as Biomarkers
Muneesh Tewari, M.D., Ph.D., Associate Professor, Internal Medicine and
Biomedical Engineering & Ray and Ruth Anderson-Laurence M. Sprague
Memorial Research Professor, University of Michigan Health System
MicroRNAs as well as other classes of RNA have been found to be
present in blood and other biofluids in extracellular form and are being
actively investigated as biomarkers for cancer and many other diseases.
I review some of the history of this field, current knowledge about
circulating microRNA biochemistry, key considerations and pitfalls to
avoid in performing extracellular RNA biomarker studies, as well as the
outlook for the future.
2:45The Biology of Circulating MicroRNAs in Cardiovascular
Health and Disease
Stephen Y. Chan, M.D., Ph.D., Director, Center for Pulmonary Vascular Biology
and Medicine; Associate Professor of Medicine, Department of Medicine,
University of Pittsburgh Medical Center
Plasma-based circulating microRNAs have attracted attention in cardiovascular
medicine, relevant for the study of disease states and normal physiology. I
describe our recent findings regarding the dynamic regulation and biological
actions of circulating microRNAs in aerobic exercise and in pulmonary
hypertension. I discuss new technologies to detect and quantify these factors.
Finally, I discuss the potential utility of circulating microRNAs as putative
cardiovascular biomarkers and/or therapeutic targets.
3:15 Sponsored Presentation (Opportunity Available)
3:30 Refreshment Break in the Exhibit Hall with Poster Viewing
4:00 Comparison of Extracellular RNA Profiles across Biofluids
andTheir Utility for Biomarker Development
Kendall Van Keuren-Jensen, Ph.D., Associate Professor, Neurogenomics, TGen
Examination of RNA species from several biofluids can provide a range of
information about an individual. For example, there are varying amounts of
tissue-specific data and exogenous RNA species present among different
biofluids. Depending on the type of disease or location of injury, the choice of
biofluid may be an important consideration for biomarker development.
4:30 tRNA Fragments Join the Repertoire of Small RNAs with
Potential as Biomarkers
Lynne T. Bemis, Ph.D., Chair, Biomedical Sciences, University of Minnesota
tRNA fragments are often abundant in high-throughput studies of extracellular
RNA. Initially regarded as breakdown products of mature tRNA, and thus of
little consequence, they are now being studied for their regulatory function
in health and disease. A review of our current understanding of the functions
attributed to these fragments will be presented.
5:00 Close of Conference
Liquid Biopsy:An Emerging Market for Radically Improved Cancer Management
Cancer diagnostics based on measuring
biomarkers in tissue samples has already
in the past decade provided revolutionary
advances in diagnosis, prognosis, and
therapy selection. A major drawback of
the tissue-based approach centers on
the need for invasive surgical procedures
in sample collection, which in a great
many instances preclude following the
progression or regression of disease
during therapy.
In recent years, an impressive number
of cancer biomarker researchers have
turned their attention to the analysis of markers present in
biological fluids, which can be collected with minimal invasiveness
and permit following the disease over time. This highly dynamic
field has come to be called liquid biopsy. In the past few years
a significant and growing number of startups and several major
companies have taken up the challenge of commercializing and
offering liquid biopsy products and services to the market.
These procedures, for the most part,
query blood samples for information to
be gleaned from circulating tumor cells
(CTCs), circulating tumor DNA (ctDNA)
fragments, and extracellular vesicles (EVs).
CTCs have the longest history as subjects
for liquid biopsy. Indeed, one decade-old
commercial product has already garnered
FDA approval for in vitro diagnostic use.
Circulating tumor DNA, a more recent
entry on the liquid biopsy scene, is fast
becoming an alternative or adjunct to
CTC assays. EVs are the newest and least
developed of the three liquid biopsy sample sources, and while
highly promising, their ultimate value has yet to be fully established.
This report explores the background, history and basic research of
liquid biopsy covering the three sample categories that dominate
liquid biopsy today: circulating tumor cells (CTCs), circulating
tumor DNA (ctDNA), and extracellular vesicles (EVs, also known as
exosomes). This report also details the commercial aspects, market
dynamics, and trends of liquid biopsy.
InsightPharmaReports.com
A Division of Cambridge Healthtech Institute
Liquid Biopsy:
An Emerging Market for Radically
Improved Cancer Management
Kenneth Rubenstein, Ph.D.
ExpertIntelligenceforBetterDecisions
7. LIQUIDBIOPSYSUMMIT.COM 7
SPONSORSHIP, EXHIBIT, AND
LEAD GENERATION OPPORTUNITIES
CHI offers comprehensive sponsorship packages which include presentation
opportunities, exhibit space, branding and networking with specific prospects.
Sponsorship allows you to achieve your objectives before, during, and long
after the event. Any sponsorship can be customized to meet your company’s
needs and budget. Signing on early will allow you to maximize exposure to
qualified decision-makers.
Podium Presentations – Available within the Main Agenda!
Showcase your solutions to a guaranteed, targeted audience. Package includes a
15- or 30-minute podium presentation within the scientific agenda, exhibit space,
on-site branding, access to cooperative marketing efforts by CHI, and more.
Breakfast & Luncheon Podium Presentations
Opportunity includes a 30-minute podium presentation. Boxed lunches are
delivered into the main session room, which guarantees audience attendance
and participation. A limited number of presentations are available for
sponsorship and they will sell out quickly. Sign on early to secure your talk!
Invitation-Only VIP Dinner/Hospitality Suite
Sponsors will select their top prospects from the conference pre-registration
list for an evening of networking at the hotel or at a choice local venue. CHI will
extend invitations and deliver prospects, helping you to make the most out of
this invaluable opportunity. Evening will be customized according to sponsor’s
objectives i.e.:
• Purely social • Focus group
• Reception style • Plated dinner with specific conversation focus
Exhibit
Exhibitors will enjoy facilitated networking opportunities with qualified
delegates. Speak face-to-face with prospective clients and showcase your latest
product, service, or solution.
One-on-One Meetings
Select your top prospects from the pre-conference registration list. CHI will
reach out to your prospects and arrange the meeting for you. A minimum
number of meetings will be guaranteed, depending on your marketing
objectives and needs. A very limited number of these packages will be sold.
Additional branding and promotional opportunities are available, including:
• Conference Tote Bags
• Literature Distribution (Tote Bag
Insert or Chair Drop)
• Badge Lanyards
• Padfolios
• Program Guide Advertisement
Looking for additional ways to drive leads to your sales team?
CHI’s Lead Generation Programs will help you obtain more targeted, quality
leads throughout the year. We will mine our database of 800,000+ life science
professionals to your specific needs. We guarantee a minimum of 100 leads
jper program! Opportunities include:
• Whitepapers • Web Symposia
• Custom Market Research Surveys • Podcasts
For sponsorship and exhibit information, please contact:
Terry Manning, Business Development Manager
781-972-1349 | tmanning@healthtech.com
OFFICIAL PUBLICATION LEAD SPONSORING PUBLICATIONS SPONSORING PUBLICATIONS
WEB PARTNERS
HOTEL & TRAVEL INFORMATION
Conference Venue and Hotel:
Hotel Kabuki
1625 Post Street
San Francisco, CA 94115
Phone: 415-922-3200
Reservations: Go to the travel page of LiquidBiopsySummit.com
Discounted Room Rate: $209 s/d
Discounted Room Rate Cut-off Date: May 26, 2016
Reservations and AdditionalTravel Information:
Go to the travel page of LiquidBiopsySummit.com
8. Please refer to the Registration Code below:
How to Register: LiquidBiopsySummit.com
reg@healthtech.com • P: 781.972.5400 or Toll-free in the U.S. 888.999.6288
Please use keycode
CFDX F
when registering!
Pricing and Registration Information
SHORT COURSE PRICING
Academic, Government,
Commercial Hospital-affiliated
Short Course Only $699 $399
Thursday, June 23 SC1: Molecular Beacons; Stellaris FISH Probes; and SuperSelective PCR Primers for Liquid Biopsies
SYMPOSIUM PRICING
Symposium Only $999 $599
Wednesday, June 22 S1: Circulating Markers in Cancer: Tools for Identification, Evaluation and Translation
CONFERENCE PRICING
STANDARD PACKAGE (Includes Symposium & Conference Program. Excludes Short Course.)
Early Registration Discount until March 18, 2016 $2199 $1129
Advance Registration Discount until May 13, 2016 $2349 $1179
Registrations after May 13, 2016, and on-site $2549 $1249
BASIC PACKAGE (Includes Conference Program Only. Excludes Symposium and Short Course.)
Early Registration Discount until March 18, 2016 $1549 $729
Advance Registration Discount until May 13, 2016 $1749 $799
Registrations after May 13, 2016, and on-site $1949 $879
INSIGHT PHARMA REPORT PRICING
INSIGHT PHARMA REPORT: LIQUID BIOPSY (Order Insight Pharma Report at Special Discounted Rate)
Liquid Biopsy Report $1100 $700
CONFERENCE DISCOUNTS
Poster Submission - Discount ($50 Off): Poster abstracts are due by May
13, 2016. Once your registration has been fully processed, we will send an
email containing a unique link allowing you to submit your poster abstract.
If you do not receive your link within 5 business days, please contact
jring@healthtech.com. *CHI reserves the right to publish your poster title
and abstract in various marketing materials and products.
REGISTER 3 - 4th IS FREE: Individuals must register for the same confer-
ence or conference combination and submit completed registration form
together for discount to apply.
Group Discounts: Discounts are available for multiple attendees from the
same organization. For more information on group rates contact
David Cunningham at +1-781-972-5472
Alumni Discount - SAVE 20%: CHI appreciates your participation at our events.
As a result of the great loyalty you have shown us, we are pleased to extend to
you the exclusive opportunity to save an additional 20% off the registration rate.
ADDITIONAL REGISTRATION DETAILS
Each registration includes all conference
sessions, posters and exhibits, food functions,
and access to the conference proceedings link.
Handicapped Equal Access: In accordance with
the ADA, Cambridge Healthtech Institute is
pleased to arrange special accommodations
for attendees with special needs. All requests
for such assistance must be submitted in
writing to CHI at least 30 days prior to the start
of the meeting.
To view our Substitutions/Cancellations
Policy, go to healthtech.com/regdetails
Video and or audio recording of any kind is
prohibited onsite at all CHI events.
Reports designed to keep life science professionals
informed of the salient trends in pharma technology,
business, clinical development, and therapeutic
disease markets
InsightPharmaReports.com
Contact Adriana Randall,
arandall@healthtech.com, +1-781-972-5402.
Barnett is a recognized leader in clinical
education, training, and reference guides for
life science professionals involved in the drug
development process. For more information,
visit BarnettInternational.com.
Complimentary news delivered to your inbox
Insights on the innovation between clinical
trial management and delivery of care.
ClinicalInformaticsNews.com
News on the data deluge in petascale
computing and the tools to deliver
individualized medicine.
Bio-ITWorld.com
Emerging Technologies in Diagnostics
DiagnosticsWorldNews.com
Cambridge Healthtech Institute
250 First Avenue, Suite 300
Needham, MA 02494
www.healthtech.com
Fax: 781-972-5425
LIQUIDBIOPSYSUMMITTHE
JUNE 22 - 24, 2016 HOTEL KABUKI | SAN FRANCISCO, CALIFORNIA
If you are unable to attend but would like to purchase The Liquid Biopsy
Summit 2016 CD for $350 (plus shipping), please visit LiquidBiopsySummit.
com. Massachusetts delivery will include sales tax.